Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) does not recommend ranibizumab (Lucentis®) for use within NHS Scotland for the treatment of visual impairment due to diabetic macular oedema in adults.
The drug advice notes that ranibizumab significantly improved visual acuity over 12 months compared with standard laser photocoagulation treatment; however the manufacturer's justification of the treatment's health benefits in relation to its cost was deemed to be insufficient. In addition, the manufacturer did not present a sufficiently robust economic analysis (Read more...)